Request ConsultationTargeted therapy is changing cancer care by helping doctors select treatments based on specific genetic changes and molecular features of tumors. Advances in precision medicine, biomarker testing, and drug development are creating new options while challenges such as treatment resistance, high costs, and limited access remain.
Cancer treatment is entering a new phase as researchers increasingly focus on the molecular changes responsible for disease development and progression. Traditional treatments, including chemotherapy and radiation therapy is creating additional options by focusing on specific proteins, genes, and biological pathways that help cancer cells grow and survive.
Targeted therapy uses medicines designed to interface with particular molecular targets associated with cancer. Unlike conventional chemotherapy, which can affect both cancerous and healthy rapidly dividing cells, these treatments are developed to act on selected biological mechanisms. Their effectiveness depends on the cancer type, the molecular characteristics of the tumor, and whether the targeted pathways play an important role in disease progression.
Recent regulatory developments demonstrate how quickly this field is advancing. The U.S> Food and Drug Administration (FDA) has continued to approve therapies addressing specific molecular alterations, including treatments for certain lung cancers and difficult-to-treat pancreatic cancer. These developments highlight the growing importance of precision medicines, biomarker testing, and clinical research in expanding treatment choices.
The FDA coverage available through Regulatory News provides a useful starting point for understanding regulatory development across medicines, biologics, diagnostics, and advanced therapies.
Could targeted therapy change treatment options for cancer patients? Its potential extends beyond introducing new medicines. It could help clinicians select treatments more precisely, encouraging earlier, and support the development of personalized treatment strategies. However, clinical evidence, treatment resistance, affordability, and patient eligibility will determine how broadly these benefits can be achieved.
Understanding the Growing Role of Targeted Therapy
Targeted therapy is a form of cancer treatment that targets specific molecules involved in tumor growth, progression, or survival. These molecules may include progression, or survival. These molecules may include proteins, receptors, enzymes, or signaling pathways affected by genetic changes within cancer cells.
Cancer is not a single disease. Even tumors originating in the same organ can have different molecular charateristics, which may influence how they respond to treatment. Targeted medicines aim to address these differences by identifying biological features that make certain tumors vulnerable to particular drugs.
For example, some cancers develop because of changes in genes that regulate cell growth. Other tumors produce unusually high levels of specific proteins or depend on signaling pathways that remain continuously active. Targeted medicines aim to address these differences by identifying biological features that make certain tumors vulnerable to particular drugs.
For example, some cancers develop because of changes in genes that regulate cell growth. Other tumors produce unusually high levels of specific proteins or depend on signaling pathways that remain continuously active. Targeted medicines can block these mechanisms, potentially slowing tumor growth or causing cancer cells to die.
Molecular profiling and biomarker testing are therefore important components of targeted treatment. Depending on the cancer and available testing methods, clinicians may examine tumor tissue, blood samples, or other biological material to identify alterations associated with approved therapies.
Targeted therapy is already used across several cancer types, including certain breast cancers, lung cancers, colorectal cancers, and blood cancers. Nevertheless, not every patient has a suitable molecular target, and some tumors contain multiple alterations that complicate treatment selection.
Its growing role reflects a shift toward selecting treatment according to both where cancer develops and the biological charateristics driving its progression.
Why Targeted Therapy Could Change Cancer Treatment
More Personalized Treatment Decision
One of the most important advantage of targeted therapy o sots potential to make cancer treatment more personalized. Instead of relying exclusively on the location and stage of a tumor, clinicians can consider its molecular profile when choosing an appropriate medicine.
For example, patients with certain lung cancers may benefit from therapies designed for specific genetic alterations, while some breast cancers can be treated with medicines targeting hormone receptor ot HER2-related pathways.
These approaches may help identify treatments for patients whose tumors are unlikely to respond to medicines. It can also reduce the need to use treatments that are unlikely to provide meaningful benefits when a validated biomarker indicates a better-supported alternative.
However, personalized treatment does not guarantee success. The presence of a biomarker must be interpreted alongside clinical evidence, disease stage, previous treatment, other medical conditions, and the patient’s overall health.
New Options for difficult-to-Treat Cancers
Targeted drug development is particularly important for cancers that have historically improtant for cancers that have historically presented significant treatment challenges.
Pancreatic cancer is one example. Its complex biology and frequent diagnosis at advanced stages have contributed to poor outcomes for many patients. Researchers are investigating medicines that interfere with molecular pathways involved in pancreatic tumor growth, including pathways associated with RAS proteins.
In August 2026, the FDA approved daraxonrasib, marketed as RASONQUE, for adults with metastatic pancreatic adenocardcinoma who have received at least one previous systemic therapy or are not candidates for multigene systemic treatment. The medicine inhibits the RAS GTPase family, a group of proteins involved in cancer-related signaling.
The approval represents an important development in treatment options for this difficult-to-treat disease. IT also illustrates how research into previously challenging molecular targets can lead to new therapeutic approaches.
Nevertheless, a new approval does not mean that every patient will respond or that established treatment options are no longer needed. Long-term outcomes, safety monitoring, and evidence from ongoing clinical use remain important.
Greater Use of Biomarker Testing
The development of targeted medicines is increasing the importance of diagnostic technologies that identify suitable patients.
Biomarker testing can help determine whether a tumor contains a genetic mutation, gene fusion, protein expression pattern, or other feature associated with a particular treatment. These tests may use tissue-based molecular analysis, immunohistochemistry, or blood-based methods, depending on the clinical situation.
Companion diagnostics are especially important when a medicine is approved for patients whose cancers have a specific molecular characteristic. In such cases, treatment selection may depend on an FDA-authorised or FDA- approved test, as specified in the medicine’s labelling.
As testing technologies improve, clinicians may be able to identify more treatment-relevant alterations and evaluate tumor biology with greater detail.
However, testing availability remains uneven across healthcare systems. Sample quality, testing costs, turnaround time, and access to specialist laboratories can affect whether patients receive results quickly enough to inform treatment decisions.
Opportunities for Combination Treatments.
Targeted medicines are increasingly being investigated alongside other cancer treatments, including chemotherapy, hormone therapy, immunotherapy, and additional targeted agents.
Combination approaches may be useful when tumors depend on several biological pathways or develop mechanisms that reduce their sensitivity to a single medicine. BY acting on different mechanisms, appropriately selected combinations may improve disease control in certain settings.
For example, treatment strategies for some hormone receptor-positive breast cancers combine endocrine therapy with medicines that inhibit proteins involved in cell-cycle regulation. Other approaches combine targeted drugs with treatments that stimulate or support the immune system.
The effectiveness of a combination depends on the cancer type, treatment sequence, patient charateristics, and supporting clinical evidence. Combining medicines can also increase toxicity, drug interactions, treatment complexity, and cost.
Consequently, researchers must establish whether the additional clinical benefits justify the risks before combination regimens become part of routine practice.
Recent FDA Developments Supporting Targeted Therapy
Recent regulatory decisions highlight how targeted treatment is expanding across types and molecular subgroups. These developments also highlight molecular subgroups. These developments also demonstrate the importance of linking drug approvals to defined patient populations and clinical evidence.
Sevabertinib for HER2-Mutated Lung Cancer
In September 2026, the FDA granted accelerated approval to sevabertinib, marketed as Hyrnuo, for adults with locally advanced metastatic nonsquamous non-small cell lung cancer carrying HER2 (ERBB2) tyrosine kinase domain activating mutations, identified using an FDA-authorized test. The approval introduced a targeted treatment option for this molecularly defined patient population.
This development demonstrated how identifying a specific genetic alteration can guide treatment selection. It also reinforces the role of molecular testing in matching patients with therapies designed to interfere with cancer-driving signals.
Accelerated approval allows certain medicines addressing serious conditions to reach patients based on evidence supporting a reasonably likely clinical benefit, subject to applicable requirements for confirming benefit. Continued clinical evaluation remains important.
Daraxonrasib for Metastatic Pancreatic Cancer
The FDA approved daraxonrasib in August 2026 for eligible adults with metastatic pancreatic adenocarcinoma following previous systemic treatment or who are not candidates for multiagent systemic therapy. The medicine targets RAS proteins, which play a central role in cellular signaling and cancer development.
The approval illustrates progress in developing treatments for cancers driven by molecular pathways that have historically been difficult to target. It may expand the option available to eligible patients, although treatment decisions must still account for individual clinical circumstances and the medicine’s approved indications.
Lirafugratinib for Cholangiocarcinoma
In September 2026, the FDA approved Lirafugratinib for adults with previously treated, unresectable, locally advanced, or metastatic cholangiocarcinoma carrying an FGFR2 gene fusion or other rearrangement. This approval demonstrates how targeted treatment can address molecular alteration in a relatively uncommon cancer.
Such developments are particularly relevant to patients with rare or difficult-to-treat tumors, where identifying a specific molecular target may help clinicians consider options beyond conventional treatment approaches.
Together, these examples show that targeted therapy is not a single technology or treatment category. It encompasses different medicines designed for distinct biological mechanisms and patient populations.
How Technology is Advancing Targeted Drug Development
Scientific and technological advances are helping researchers discover molecular targets, identify suitable patients, and evaluate treatment responses.
Artificial intelligence and computational biology can support the analysis of large biological datasets, help researchers identify potential drug targets, and prioritize compounds for further investigation. These tools may accelerate parts of drug discovery, although laboratory experiments and clinical studies remain necessary to establish safety and effectiveness.Next-generation sequencing enables researchers and clinicians to examine multiple genetic alterations within a tumor. Broader molecular profiling may identify treatment-relevant biomarkers that would otherwise remain undetected.
Liquid biopsies use biological samples, including blood, to detect certain tumor-associated genetic material. In appropriate clinical settings, they may help assess tumor alterations or monitor changes over time. However, they do not replace tissue testing in every situation, and a negative may not exclude the presence of a relevant alteration.
Advanced drug design is also expanding the range of possible treatment strategies. Researchers are investigating improved inhibitors, antibody-drug conjugates, and other approaches intended to deliver treatment to cancer cells or interfere with specific biological processes.
These advances could improve the identification of therapeutic targets and support more informed clinical decisions. Their practical value will depend on analytical accuracy, clinical validation, regulatory oversight, and integration into healthcare workflows.
Key Challenges That Could Limit Adoption
Despite its promise, targeted therapy faces several challenges that may influence its future development and accessibility.
- Treatment resistance: Cancer cells can acquire new mutations or activate alternative signaling pathways, allowing tumors to continue growing despite treatment. Researchers are investigating next-generation medicine and combination strategies to address resistance.
- Limited patient eligibility: A targeted medicine may benefit only patients whose tumors contain a particular alteration. Patients without the relevant biomarker may need other treatment approaches.
- High development costs: Drug discovery, molecular testing, clinical trials, and regulatory submission require substantial investment. These costs can contribute to high treatment prices.
- Safety and tolerability: Targeted medicines can still cause significant adverse effects. Their effects on normal tissues and other biological pathways must be evaluated through clinical trials and ongoing safety monitoring.
- Unequal access to testing: Advanced diagnostic facilities and specialist expertise may not be available in every region. Delays in testing can affect treatment selection, while financial barriers may prevent some patients from obtaining recommended therapies.
- Regulatory and evidence requirements: Medicines must demonstrate an appropriate benefits-risk profile for their intended uses. Accelerated pathways may provide earlier access in certain circumstances, but confirmatory evidence and continued monitoring can remain essential.
Addressing these challenges will require collaboration among pharmaceutical companies, diagnostic developers, healthcare professionals, regulators, and healthcare systems.
What the Future Holds for Targeted Therapy
The future of targeted therapy will likely depend on the ability to identify new molecular targets and determine which patients are most likely to benefit from available treatments.
Researchers are exploring therapies that address complex tumor biology, including multiple signaling mechanisms and changes that emerge during treatment. Advances in genomic analysis may also support the identification of additional biomarkers and improve understanding of why certain patients respond differently to the same medicine.
Another important opportunity lies in integrating targeted therapies with other treatment modalities. Carefully designed combinations may improve outcomes for selected patients, provided clinical studies demonstrate that the benefits outweigh additional risks.
Real-world evidence and long-term safety monitoring will also contribute to understanding how these medicines perform outside clinical trials. Such evidence can help identify uncommon adverse effects, evaluate treatment use across different patient populations, and inform future research.
For healthcare systems, the priority will be to ensure that innovation translates into meaningful patient benefits. This includes improving access to validated diagnostic testing, supporting appropriate clinical expertise, and developing sustainable approaches to treatment affordability.
Conclusion
Targeted therapy could significantly change cancer treatment options by directing medicines toward specific molecular mechanisms involved in tumor growth and survival. Advances in biomarker testing, precision medicine, and drug development are helping researchers identify treatments for patients with particular genetic alterations and expand possibilities for difficult-to-treat cancers.
Recent FDA decisions involving sevabertinib, daraxonrasib, and lirafugratinib illustrate how targeted medicines are addressing distinct molecular features across different cancer types. These developments reinforce the importance of matching treatments to tumor biology rather than relying exclusively on the cancer's location or stage.
However, targeted therapy is not a universal solution. Treatment resistance, limited eligibility, adverse effects, high costs, and unequal access to molecular testing remain significant challenges. Clinical evidence and regulatory oversight will continue to determine where these medicines provide meaningful benefits.
Ultimately, targeted therapy's greatest contribution may be its ability to make cancer care more individualized. Continued scientific research, reliable diagnostics, and equitable access will be essential to converting promising discoveries into safe, effective, and accessible treatment options for patients.
About the Authors
Aditi Shivarkar
Aditi, Vice President at Precedence Research, brings over 15 years of expertise at the intersection of technology, innovation, and strategic market intelligence. A visionary leader, she excels in transforming complex data into actionable insights that empower businesses to thrive in dynamic markets. Her leadership combines analytical precision with forward-thinking strategy, driving measurable growth, competitive advantage, and lasting impact across industries.
Aman Singh
Aman Singh with over 13 years of progressive expertise at the intersection of technology, innovation, and strategic market intelligence, Aman Singh stands as a leading authority in global research and consulting. Renowned for his ability to decode complex technological transformations, he provides forward-looking insights that drive strategic decision-making. At Precedence Research, Aman leads a global team of analysts, fostering a culture of research excellence, analytical precision, and visionary thinking.
Piyush Pawar
Piyush Pawar brings over a decade of experience as Senior Manager, Sales & Business Growth, acting as the essential liaison between clients and our research authors. He translates sophisticated insights into practical strategies, ensuring client objectives are met with precision. Piyush’s expertise in market dynamics, relationship management, and strategic execution enables organizations to leverage intelligence effectively, achieving operational excellence, innovation, and sustained growth.